Extrahepatic Bile Duct Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Extrahepatic Bile Duct Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Extrahepatic bile duct cancer is a rare type of cancer that affects the ducts that carry bile from the liver or gallbladder to the small intestine. Bile is a fluid that helps digest fats and remove waste products from the body. Extrahepatic bile duct cancer can block the flow of bile, causing jaundice, itching, abdominal pain, weight loss, and other symptoms. The most common type of extrahepatic bile duct cancer is adenocarcinoma, which starts in the cells that line the ducts. The treatment and prognosis of extrahepatic bile duct cancer depend on the location and stage of the tumor, as well as the patient’s overall health and preferences.
The Extrahepatic Bile Duct Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Extrahepatic Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Extrahepatic Bile Duct Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Extrahepatic Bile Duct Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 43 molecules, with 42 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Extrahepatic Bile Duct Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Extrahepatic Bile Duct Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Extrahepatic Bile Duct Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akeso IncAlphamab Oncology
Arcus Biosciences Inc
AstraZeneca Plc
Bayer AG
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
Cantargia AB
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Compass Therapeutics Inc
Concentra Biosciences LLC
Cornerstone Pharmaceuticals Inc
Eisai Co Ltd
Everest Medicines Ltd
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Genome &, Co
Handok Inc
Huabo Biopharm (Shanghai) Co Ltd
Jazz Pharmaceuticals Plc
Leap Therapeutics Inc
Lee's Pharmaceutical Holdings Ltd
Les Laboratoires Servier SAS
MacroGenics Inc
Merck &, Co Inc
Mural Oncology Inc
National Cancer Institute US
Ohara Pharmaceutical Co Ltd
Ono Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd
Redx Pharma Plc
RenovoRx Inc
SciClone Pharmaceuticals Holdings Ltd
Shanghai Haihe Biopharma Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Simcere Pharmaceutical Group Ltd
SMT bio Co Ltd
Suzhou Hitebio Biotechnology Co Ltd
Wuhan Binhui Biopharmaceutical Co Ltd
Zai Lab Ltd
ZielBio Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Extrahepatic Bile Duct Cancer reports